Key takeaways:

Ocugen plans to submit biologics license applications for retinitis pigmentosa, Stargardt disease and geographic atrophy in the next 3 years.

Another program is focused on diabetic macular edema.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for retinitis pigmentosa, Stargardt disease and geographic atrophy.

According to Qamar, OCU400, a modifier gene therapy platform, is being investigated for syndromic and non-syndromic forms of retinitis pigmentosa in “the largest gene-agnostic trial, with 75 patients in the rhodopsin and 75 in the gene-agnostic arm.” Ocugen aims to submit a biologics license application (BLA) in 2026.

Additionally, the FDA cleared the initiation of a ph

See Full Page